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Abstract:  Non-ionic surfactant vesicles of valsartan, an angiotensin II inhibitor, were prepared by 
coacervation phase separation method. The prepared systems were characterised for encapsulation 
efficiency, shape, size and in vitro drug release. Stability study was carried out to investigate the 
leaching of drug from the proniosomal system during storage. The results showed that valsartan in all 
the formulations was successfully entrapped and a substantial change in release rate and an alteration 
in the encapsulation efficiency of valsartan from proniosomes were observed upon varying the type 
of surfactant and cholesterol content. The encapsulation efficiency of proniosomes prepared with 
Span 60 was superior to that prepared with Span 40. A preparation with 9:2:9 ratio of Span 60, 
cholesterol and lecithin gave maximum encapsulation efficiency (71.50%) and release results (Q24h= 
75%) as compared to other compositions. Proniosomal formulations showed fairly high retention of 
valsartan inside the vesicles at refrigerated temperature (4-8
oC) up to 1 month.  
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INTRODUCTION 
 
Several classes of medications collectively referred to as antihypertensive drugs are available 
for  treating  hypertension.  One such class is angiotensin II antagonists. Valsartan belongs to this 
category and is used as a choice for patients with heart failure who are unable to tolerate angiotensin 
converting enzyme (ACE) inhibitors in the management of hypertension. It is currently available as 
tablets  and  hard  gelatin  capsules  in  the  market.  The  drug  is  rapidly  absorbed  following  oral 
administration with a bioavailability of about 23% [1]. Valsartan is poorly soluble and the aqueous 
solubility is reported to be less than 1 mg/mL. It has a low molecular weight (435.5 g/mol) and 
melting point (116-117
oC) with a low partition coefficient (4.5) [1-2].    
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Some efforts have been made to enhance the solubility of valsartan to study its effect on the 
bioavailability of the drug. Valsartan/hydroxypropyl-β-cyclodextrin complex has been reported to 
significantly increase solubility and decrease the rate of valsartan degradation [3]. A Gelucire 50/13-
based dispersed granule formulation has also been reported very recently [4]. The effect of various 
terpenes including a diterpene, forskolin (a putative penetration enhancer), on skin permeation of 
valsartan  was  investigated  by  Rizwan  et  al  [5].  A  self-microemulsifying  drug  delivery  system 
(SMEDDS)  has  been  developed  by  Dixit  et  al.  [6]  to  enhance  the  diffusion  rate  and  oral 
bioavailability of valsartan.  
Vesicular carriers such as liposomes or niosomes have distinct advantages over conventional 
dosage forms because these particles can act as drug reservoirs. In recent years, non-ionic surfactant 
vesicles, also referred to as niosomes, have been studied as an alternative to conventional liposomes 
in drug delivery [7-9]. Compared to liposomes (phospholipid vesicles), they offer higher chemical 
stability, lower cost and greater choice of surfactants. However, even though niosomes exhibit good 
chemical stability during storage, there may be problems of physical stability in niosomal dispersions. 
Aqueous suspensions of niosomes may exhibit aggregation, fusion, leaking of entrapped drug or 
hydrolysis of encapsulated drug, thus limiting the shelf life of the dispersion [10].  
The  proniosomal  approach  minimises the above-mentioned problems, as it involves a dry 
product or a liquid crystalline gel that can be hydrated immediately before use [11-12]. Ease of 
transfer,  distribution,  measuring  and  storage  makes  proniosomes  a  versatile  delivery  system. 
Proniosomes are water-soluble carrier particles that are coated with surfactant and can be hydrated 
to form a niosomal dispersion immediately before use on brief agitation in hot aqueous media [13]. 
Various  studies  have  demonstrated  the  successful  use  of  proniosomes  for  delivery  of 
antihypertensive  drugs.  For  instance,  Blazek-Welsh  and  Rhodes  [14]  prepared  proniosomes  of 
alprenolol  hydrochloride  using  Span  60,  dicetyl  phosphate  and  cholesterol  by  slurry  method. 
Maltodextrin was used as carrier that produced proniosomes with greater drug loading. Gupta et al. 
[15] investigated the potential of proniosomes as a transdermal drug delivery system for captopril. 
Proniosomes were found promising for transdermal delivery of this drug leading to a reduction in 
side effects. Thakur et al. [16] reported a proniosomal transdermal therapeutic system  for losartan 
potassium . 
The  aim  of  this  study  is  to  investigate  the  feasibility  of  formulation  of  proniosomes  of 
valsartan. Vesicles prepared were characterised by optical, scanning and transmission microscopy for 
vesicle formation and morphology. Drug encapsulation efficiency and release studies were carried 
out.  Finally,  a  stability study of proniosomal formulations was also performed to investigate the 
leaking of the drug during storage.  
 
MATERIALS AND METHODS   
 
Chemicals and Reagents    
Sorbitan  monopalmitate  (Span  40)  and  sorbitan  monostearate  (Span  60)  were  purchased 
from Shah Scientific, Mumbai, India. Soya lecithin (95%) was obtained as a gift sample from Ind 
Swift, Parwanu, India. Cholesterol (AR grade) was purchased from Central Drug House Pvt. Ltd, 
New  Delhi,  India.  Absolute  ethanol  was  purchased  from  Changshu  Yangyuan  Chemical,  China.  
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Disodium hydrogen phosphate, sodium chloride and potassium dihydrogen phosphate (AR grades) 
were purchased from Qualigens Fine Chemicals Ltd. Mumbai, India for preparation of phosphate 
buffer  saline  (PBS,  pH  7.4).  Valsartan  (99.8%)  was  obtained  as  a  gift  sample  from  Jubilant 
Organosys,  Noida,  India.  Dialysis  membrane  (MW  cut-off:  8000-10,000)  was  purchased  from 
Himedia Laboratories Pvt. Ltd, Mumbai, India.  
 
Equipment 
 
Valsartan  was  estimated  in  samples  by  a  UV-spectrophotometer  (UV-1800,  Shimadzu, 
Japan). A light microscope with digital camera (Coolpix S 220, Nikon, Japan), a scanning electron 
microscope (JSM-6100, Jeol, Japan) and a transmission electron microscope (Hitachi 7500, Canada) 
were used for morphological characterisation of vesicles. The pH of PBS was set using a pH meter 
(Max 962-P, Max Electronics, India). A centrifuge (REMI Group, Mumbai, India) and a sonicator 
(Power Sonic 410, India) were used. 
 
Preparation of Proniosomes and Niosomes 
 
Valsartan  proniosomes  were  prepared  by  coacervation  phase  separation  method  (method 
modified  from  literature  by  Perrett  et  al.  [17]).  The  composition  of  different  proniosomal 
formulations is listed in Table 1. Briefly, drug (valsartan), surfactant (Span 40 or Span 60), lecithin 
and cholesterol were mixed with 2.5 ml of absolute ethanol in a wide-mouth glass tube. The tube was 
covered with a lid and warmed for 5 min at 65±3
oC in a water bath. PBS (1.6 ml) was added and the 
mixture was further warmed for about for 2 min so that a clear mixture was obtained. It was allowed 
to cool at room temperature until the dispersion was converted to a proniosomal gel. The gel was 
transformed to niosomes by hydrating with PBS (10 ml) at 80
oC by gentle mixing. The niosomes 
were sonicated twice for 30 seconds each with a sonicator and then used for further study [14].   
 
               Table 1.  Composition of  proniosomal formulations prepared 
 
Proniosomal code  Drug  
(mg) 
Span 60 
(mg) 
Span 40 
(mg) 
Lecithin 
(mg) 
Cholesterol 
(mg) 
PN 1  100  1800  -  1800  200 
PN 2  100  1800  -  1800  400 
PN 3  100  1800  -  900  200 
PN 4  100  -  1800  1800  200 
PN 5   100  -  1800  1800  400 
PN 6  100  -  1800  900  200 
 
Determination of Encapsulation Efficiency    
Per  cent  encapsulation  efficiency  (EE)  was  determined  by  centrifugal  method  [18].  The 
proniosomal gel was converted to a niosomal dispersion, which was centrifuged (18000 rpm) for 40 
min at 5
oC in order to separate unentrapped drug.  The supernatant was taken and diluted with PBS. 
The drug concentration in the resulting solution was assayed spectrophotometrically at 250 nm. The  
Maejo Int. J. Sci. Technol.  2011, 5(01), 146-158   
 
 
149
percentage of drug  encapsulation was calculated by the following: EE (%) = [(Ct - Cf)/ Ct] × 100, 
where Ct is the concentration of total drug and Cf is the concentration of unentrapped drug. 
 
Characterisation of Valsartan Proniosomes 
 
Optical microscopy and vesicle size determination   
A drop of niosomal dispersion prepared from proniosomes was spread on a glass slide and 
examined for the vesicle structure and presence of insoluble drug crystals under the light microscope 
with varied magnification power. Photomicrographs were taken for niosomes using a digital camera 
with 6X optical 200 m. 
The proniosomal gel (100 mg) was hydrated with PBS (10 ml) in a small test tube by manual 
shaking for 5 min and the resulting niosomes were observed under optical microscope at 100 X 
magnification.  The  average  size  of  vesicles  was  measured  using  calibrated  ocular  and  stage 
micrometer in the microscope. 
 
Scanning electron microscopy   
   The niosomes formed from the hydration of proniosomal gel were mounted on an aluminum 
stub  with  double-sided  adhesive  carbon  tape.  The  vesicles  were  then  sputter-coated  with 
gold/palladium  using  a  vacuum  evaporator  and  examined  with  the scanning electron microscope 
equipped with a digital camera at 25kV accelerating voltage [19]. 
 
Transmission electron microscopy   
The morphology of the hydrated niosomal dispersions prepared from proniosomes was also 
determined by transmission electron microscopy. A drop of niosomal dispersion was applied to a 
carbon-coated 300-mesh copper grid and left to adhere on the carbon substrate for about 1 min. The 
remaining dispersion was removed by a piece of filter paper. A drop of 2% aqueous solution of 
uranyl acetate was applied for 35 seconds and again the solution in excess was removed by the tip of 
filter paper. The sample was air-dried and observed under the transmission electron microscope at 
90kV [13]. 
 
 In vitro release study   
In vitro release pattern of niosomal suspension prepared from proniosomes (as prescribed 
above) was carried out using a dialysis bag (high-media dialysis membrane, 8000-10,000 MW cut-
off) as a donor compartment [20]. An accurately measured amount of valsartan niosomes, equivalent 
to 20 mg valsartan, were taken in the dialysis membrane and  placed in a beaker containing 75 ml of 
PBS, which acted as receptor compartment. Previously, the dialysis membrane was soaked in warm 
water for 10 min and both ends were sealed with closure clips after adding the niosomal preparation. 
The  beaker  was  placed  over  a  magnetic  stirrer  (100  rpm)  and  maintained  at  37±1
oC.  At 
predetermined time intervals during 24 hr, aliquots (1ml) were withdrawn and replaced with fresh 
buffer. The sink condition was maintained throughout the experiment. The withdrawn samples were 
appropriately diluted and analysed for drug content spectrophotometrically at 250 nm using PBS as 
blank. The results were the mean values of three runs.   
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Stability of valsartan proniosomes 
 
A physical stability test was carried out to investigate the leaching of drug from proniosomes. 
The proniosomal samples were sealed in 20-ml glass vials and stored at refrigeration temperature (4-
8
oC) and at 37
oC for one month. The EE of all the samples was determined in the same manner as 
prescribed previously after one month [21]. 
 
Statistical analysis 
 
Statistical  analyses  of  %  EE  and  in  vitro  release  of  the  proniosomal  formulations  were 
performed using one-way analysis of variance (1-way ANOVA) and paired t-test respectively (Graph 
Pad, version 3.0, San Diego, CF). The level of significance was taken at p value < 0.05. 
 
RESULTS AND DISCUSSION  
  
Optical Microscopy and Vesicle Size Determination   
The  photomicrographs  of  hydrated  PN1  and  PN2  proniosomal  formulations  (Table  1), 
composed of Span 60 and cholesterol in 9:1 and 4.5:1 ratios, are shown in Figure 2 and Figure 3 
respectively.  The  photographs  reveal  that  the  niosomes  are  unilamellar  vesicles  having  spherical 
shape and no aggregation or agglomeration is observed. Apparently, PN1 niosomal formulation gives 
vesicles of larger sizes. 
   
 
 
            
Figure 2.  Photomicrograph of hydrated PN1 proniosomal formulation 
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     Figure 3.  Photomicrograph of hydrated PN2 proniosomal formulation  
The mean particle sizes of all the hydrated proniosomal formulations are shown in Table 2, 
which shows that the niosomes composed of Span 60 are larger in sizes than those obtained using 
Span 40. Span 60 has longer saturated alkyl chains compared to Span 40 [22] and it was reported 
that surfactants with larger alkyl chains generally give larger vesicles [23]. This seems to account for 
the  high  EE  obtained  with  Span  60  proniosomes.  Moreover,  increasing  cholesterol  content  or 
reducing lecithin content contributed to an increase in hydrophobicity with consequent reduction in 
vesicle sizes as listed in Table 2.   
 
Scanning and Transmission Electron Microscopy 
 
Results of scanning and transmission electron microscopic study of niosomes prepared from  
PN1 and PN2 proniosomal formulations are shown in Figures 4-7. Most of the vesicles are well 
identified, spherical and discreet with sharp boundaries having large internal aqueous space. 
 
Encapsulation Efficiency  
 
The EE of all proniosomal formulations are reported in Table 2. From the table, increase in 
cholesterol, one of the common additives for preparing stable proniosomes, is seen to increase EE of 
valsartan.  An  increase  in  cholesterol  content  has  also  been  found  to  result  in  increase  in 
microviscosity of the membrane leading to more rigidity of the bilayers [23]. Cholesterol seems to 
have an ability to cement the leaking space in a bilayer membrane [24]. 
All Span-type surfactants have the same head group with different alkyl chains. Increase in 
the alkyl chain length has been found to lead to a higher EE [25]. Span 60 has a longer saturated 
alkyl chain (C16) compared to that of Span 40 (C14). A larger alkyl chain lowers the HLB value of a 
surfactant and this tends to increase EE of the drug [22]. It is clear that the PN2 formula, which was  
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composed of Span 60, cholesterol and lecithin in a 9:2:9 ratio, seems to be the most suitable for an 
efficient encapsulation of valsartan as it exhibits the highest EE (71.5 %). 
 
 
 
 
   Figure 4.  Transmission electron micrograph of hydrated PN1 proniosomal formulation  
  (at 90 kV with magnification 100,000 X) 
 
 
 
 
  Figure 5.  Transmission electron micrograph of hydrated PN2 proniosomal formulation  
(at 90 kV with magnification 100,000 X)   
 
  
Maejo Int. J. Sci. Technol.  2011, 5(01), 146-158   
 
 
153
 
        Figure 6.  Scanning electron image of hydrated PN1 proniosomal formulation  
               (at 25 kV with magnification 2,000 X) 
 
 
 
 
      Figure 7.  Scanning electron image of hydrated PN2 proniosomal formulation  
             (at 25 kV with magnification 2,000 X) 
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            Table 2.  EE  and vesicle size of hydrated proniosomes 
 
 
 
 
 
 
 
 
 
 
In Vitro Release Study    
The dialysis method was used to investigate the in vitro valsartan release from niosomes. 
Results are shown in Figure 8. The percentage of the drug released after 24 hr from the niosomal 
vesicles are shown in Table 3. Formulations which have higher cholesterol content (PN2 and PN5) 
are seen to have less drug release over a period of 24 hr. Hence, increase in cholesterol ratio seems 
to result in a more intact bilayer and consequent reduction in permeability. 
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      Figure 8.  In vitro drug release of niosomes prepared from various proniosomal formulations 
 
 
 
 
 
Formulation  Surfactant  Lecithin 
(mg) 
Cholesterol 
(mg) 
   EE (%)  
    + S.D. 
Vesicle size       
(µm) + S.D. 
PN 1  Span 60  1800  200  66.97 ± 2.35  5.26  ± 0.46 
PN 2  Span 60  1800  400  71.47 ± 1.61  4.19 ± 0.082 
PN 3  Span 60  900  200  69.47 ± 1.16  3.61 ± 0.105 
PN 4  Span 40  1800  200  49.43 ± 2.11  3.36 ± 0.198 
PN 5   Span 40  1800  400  51.83 ± 1.59  3.03 ± 0.066 
PN 6  Span 40  900  200  43.34 ± 4.13  2.80 ± 0.025 
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                                 Table 3.  In vitro release of valsartan from niosomes prepared 
                                                 from various  proniosomal formulations after 24 hr 
      
 
 
 
 
 
 
 
 
 
 
By inspection of the data, it is also evident that proniosomal formulation with less amount of 
lecithin gives a faster rate of drug release, probably owing to disruption of structure of vesicles 
having  a  reduced  amount  of  lecithin.  However,  this  increase  in  release  rate  was  found  to  be 
insignificant (p>0.05) in both cases. Among all formulations, those with Span 40 showed statistically 
significant (p<0.05) increase in release cf. Span 60, keeping all other additives the same. The large 
vesicle size of Span 60 formulations also tends to act as barrier to the drug release thereby reducing 
it.  It is to be noted that the in vitro release results are consistent with those of EE; PN2 proniosomes 
with  highest  EE  (71.47%)  show  lowest  drug  release  (74.96%)  after 24 hr. Similar results were 
obtained by Guinedi et al. [22]. 
Mathematical  models  are  commonly  used  to  predict the  release  mechanism  and  compare  
release profile. For all the formulations (PN1 to PN6), the cumulative per cent drug release vs time 
(zero order), the cumulative per cent drug release vs square root of time (Higuchi plot), and log 
cumulative per cent drug remaining vs time (first order) were plotted separately (not shown here). In 
each  case,  r
2  value  was  calculated  from  the  graph  and  reported  in  Table  4.  Considering  the 
determination coefficients, Higuchi model was found to fit the release data best. This demonstrates 
that  valsartan  molecules  were  dispersed in the proniosomes matrix and there was no interaction 
between the drug and proniosomes material. The first order release model fitting of the release data 
shows that the release rate was concentration- dependent. It is therefore concluded that the drug was 
released from proniosomes by a diffusion-controlled mechanism. The results are in good consistency 
with the experimental results observed by Guinedi et al. [22]. 
 
Stability Studies 
 
Physical stability of proniosomal formulations were studied for a period of one month. The 
EE were determined for all proniosomal formulations stored at 4-8
oC and 37
oC as shown in Figure 9, 
which indicates insignificant decrease in EE of proniosomes stored at 4-8
oC: approximately 90% of 
valsartan was retained in all proniosomal formulations after the one-month period. Thus, both Span 
40 and Span 60 proniosomes of valsartan seemed to exhibit good stability at low temperature.  
 
Formulation  Per cent release ± S.D. 
PN 1  78.05 ± 1.87 
PN 2  74.96 ± 2.23 
PN 3  83.02 ± 0.62 
PN 4  82.08 ± 1.37 
PN 5   81.01 ± 2.31 
PN 6  88.09 ± 0.34  
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                  Table 4.  Kinetic analysis release data of valsartan proniosomal formulations  
 
 
 
 
 
 
 
 
 
 
 
 
   
      Figure 9.  Comparison of EE of valsartan proniosomal formulations after one month 
 
CONCLUSIONS 
 
Using coacervation phase separation method, valsartan has been successfully incorporated in 
proniosomal formulations which can be potentially useful for delivery of this drug. Results of the 
present  work  have  shown  that  surfactant  type  and  content  of  cholesterol  and  lecithin affect the 
encapsulation  efficiency  and  drug  release  rate  from  proniosomes.  A  maximum  encapsulation 
efficiency of 71% and drug release of 88% after 24 hr have been attained. Encapsulation efficiency of 
proniosomes formed by Span 60 was observed to be higher compared to that obtained with Span 40. 
Valsartan proniosomes were also found to be quite stable at 4-8
oC over a one-month period. This 
work has established the foundation for future study on the potential of valsartan-loaded niosomes 
for a transdermal delivery system.   
Formulation  Zero order (r
2)  Higuchi model (r
2)  First order (r
2) 
PN 1  0.886  0.986  0.982 
PN 2  0.885  0.974  0.969 
PN 3  0.852  0.965  0.958 
PN 4  0.849  0.958  0.944 
PN 5   0.871  0.966  0.962 
PN 6  0.813  0.953  0.951 
E
E
 
(
%
)
 
Formulation  
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